Market Overview

UPDATE: Piper Jaffray Initiates ZIOPHARM Oncology at Neutral on 2013 Cancer Development Outlook

Share:
Related ZIOP
10 Biggest Mid-Day Losers For Friday
Mid-Day Market Update: U.S. Stocks Turn Lower; Iteris Shares Climb Following Q1 Sales Outlook

Piper Jaffray initiated coverage on ZIOPHARM Oncology (NASDAQ: ZIOP) with a Neutral rating and a $5.00 price target.

Piper Jaffray said, "The company's management deploys its considerable oncology network to focus on developing improved chemotherapeutics, and we believe its lead candidate palifosfamide (pali', DNA-alkylator), will succeed in at least one indication based on clinical rationale and early data. Pali' is currently in two Phase III studies, for 1st-line soft tissue sarcoma (STS) and for 1st-line small-cell lung cancer (SCLC). That said, we are not sufficiently convinced by the stated PFS-driven regulatory strategy to make a call on the near term pivotal PFS data in STS."

ZIOPHARM Oncology closed at $4.18 on Thursday.

Latest Ratings for ZIOP

DateFirmActionFromTo
Jun 2016Raymond JamesInitiates Coverage onMarket Perform
Dec 2015Wells FargoInitiates Coverage onUnderperform
Jun 2015BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for ZIOP
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (ZIOP)

View Comments and Join the Discussion!